title: Species distribution and susceptibility profile of yeasts isolated from blood cultures: results of a multicenter active laboratory-based surveillance study in Argentina.
abstract: The Mycology Department of the Instituto Nacional de Enfermedades Infecciosas "Dr. C. Malbrán", conducted the Second National Multicenter Survey on Fungemia due to Yeasts in Argentina. The aim was to obtain updated data of the frequency of the causative species encountered and their in vitro susceptibility to seven antifungal agents. Yeast species were identified by micromorphological and biochemical studies. Antifungal susceptibility testing was performed by the reference microdilution method E.Def 7.1 of the European Committee on Antibiotic Susceptibility Testing (EUCAST). A total of 461 viable yeasts were identified. The most frequent species were: Candida albicans (38.4 %), Candida parapsilosis (26 %), Candida tropicalis (15.4 %) and Candida glabrata (4.3 %). Other uncommon species, such as Candida viswanathii (0.6 %), Candida haemulonii (0.4 %), Candida inconspicua (0.2 %) and Candida fermentati (0.2 %) were also isolated. Among the Candida spp., 5.4 % and 1.6 % were resistant to fluconazole and voriconazole, respectively. Itraconazole and caspofungin were the most efficient agents against all Candida spp. tested (MIC < 1 mg/l). For anidulafungin, 21.6 % of C. parapsilosis showed a MIC value of 4 mg/l. Fluconazole was less active against 53.1 % of Cryptococcus neoformans (MIC > 8 mg/l), 75 % of Trichosporon spp., and 100 % of Rhodotorula spp., Geotrichum candidum, Saccharomyces cerevisiae. The global percentage of mortality was 20 %. The presence of uncommon species reinforces the need for performing continuous laboratory surveillance in order to monitor possible changes, not only in the epidemiological distribution of species, but also in the resistance to antifungal drugs.
authors.affiliation: Departamento Micología, Instituto Nacional de Enfermedades Infecciosas Dr. C. Malbrán, Ciudad Autónoma de Buenos Aires, Argentina. scordoba@anlis.gov.ar
authors.forename: Susana
authors.initials: S
authors.lastname: Córdoba
authors.forename: Walter
authors.initials: W
authors.lastname: Vivot
authors.forename: Maria E
authors.initials: ME
authors.lastname: Bosco-Borgeat
authors.forename: Constanza
authors.initials: C
authors.lastname: Taverna
authors.forename: Wanda
authors.initials: W
authors.lastname: Szusz
authors.forename: Omar
authors.initials: O
authors.lastname: Murisengo
authors.forename: Guillermina
authors.initials: G
authors.lastname: Isla
authors.forename: Graciela
authors.initials: G
authors.lastname: Davel
mesh_terms: D000328:Adult; D000935:Antifungal Agents / Q000494:pharmacology*; D001118:Argentina / Q000453:epidemiology; D002648:Child; D003428:Cross Infection / Q000188:drug therapy / Q000382:microbiology* / Q000401:mortality; D016208:Databases, Factual; D025141:Drug Resistance, Fungal; D026141:Drug Resistance, Multiple, Fungal; D005260:Female; D016469:Fungemia / Q000188:drug therapy / Q000382:microbiology* / Q000401:mortality; D006801:Humans; D007755:Laboratories, Hospital; D008297:Male; D008826:Microbial Sensitivity Tests; D011159:Population Surveillance; D011446:Prospective Studies; D013045:Species Specificity; D015003:Yeasts / Q000145:classification / Q000187:drug effects / Q000302:isolation & purification*
chemical_list: D000935:Antifungal Agents